Navigation Links
Helix BioPharma reports Q2 2008 highlights, financial results
Date:3/10/2008

n the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP".

The Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. Reported financial information may not necessarily be indicative of future operating results or of future financial position, due to a number of risks and uncertainties, including those set forth below. This News Release contains certain forward-looking statements and information regarding the Company's activities and finances, which statements and information can be identified by the use of forward-looking terminology such as "future", "anticipation", "planned", "expects", "continue", "developing", or variations thereon, or comparable terminology referring to future events or results. Forward looking statements and information are statements and information about the future and are inherently uncertain. Helix's actual results could differ materially from those anticipated in these forward-looking statements and information as a result of numerous risks and uncertainties including without limitation: uncertainty whether Topical Interferon Alpha-2b or L-DOS47 will be successfully developed and commercialized as a drug or at all; the need for additional clinical trials, the occurrence and success of which cannot be assured; product liability and insurance risks; research and development risks, the risk of technical obsolescence; the need for further regulatory approvals, which may not be obtained in a timely matter or at all; intellectual property risks; marketing/manufacturing and partnership/strategic alliance risks; the effect of competition; uncertainty of the size a
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... N.Y. , Aug. 21, 2014  BioSpecifics ... biopharmaceutical company developing first in class collagenase-based products ... or CCH) in the U.S. and XIAPEX ® ... significant results from a randomized, double-blind Phase 2a ... cellulite, or edematous fibrosclerotic panniculopathy. The results showed ...
(Date:8/21/2014)... Texas (PRWEB) August 21, 2014 ... Seaweed Fertilizer Industry” is a professional and ... market. The report provides basic Seaweed Fertilizer ... and industry chain structure as well as ... market analysis, including domestic market as well ...
(Date:8/21/2014)... Rochelle, N.Y. (PRWEB) August 21, 2014 ... is the first private college in the Mid-Hudson Region ... College will now begin accepting applications from qualified “high-technology” ... , “We are very pleased to have been selected ... support Governor Cuomo’s transformative initiative to stimulate economic development ...
(Date:8/21/2014)... , Aug. 21, 2014  China Cord Blood Corporation ... its plan to release financial results for the first ... 2014, after market close in the US.  ... 8:00 a.m. ET on Friday, August 29, 2014 to ... of the Company,s recent developments, followed by a question ...
Breaking Biology Technology:BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2
... Combination of Panzem(R) NCD and Avastin(R) May ... 28 EntreMed, Inc.,(Nasdaq: ENMD ), ... treatment of cancer and inflammatory diseases, today,announced ... Phase 2 multi-center,study combining Panzem(R) NCD with ...
... PARIS, January 28 Sanofi-aventis announced,today that ... approved for marketing in Japan by the ... prevention of venous thromboembolism (VTE) in patients,undergoing ... as total hip,replacement, total knee replacement and ...
... Inc.,(NYSE: FRX ), Forest Laboratories Holdings, Ltd., ... GmbH announced that they have filed a second,lawsuit ... of Delaware against,additional companies for infringement of U.S. ... Forest,s Namenda(R) product. The defendants,named in the lawsuit ...
Cached Biology Technology:EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study 2EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study 3EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study 4Clexane(R)/Lovenox(R) Approved in Japan 2Clexane(R)/Lovenox(R) Approved in Japan 3Clexane(R)/Lovenox(R) Approved in Japan 4Clexane(R)/Lovenox(R) Approved in Japan 5Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement 2
(Date:8/22/2014)... tea polyphenols are strong antioxidants and can ... spinal cord neurons against oxidative stress? Jianbo ... Hospital of Liaoning Medical University, China discovered ... stress and inhibit neuronal apoptosis, indicating green ... spinal cord neurons under oxidative stress. The ...
(Date:8/22/2014)... American consumers will finally be able to purchase fuel ... as zero-emissions vehicles, most of the cars will run ... that contributes to global warming. , Now scientists at ... uses an ordinary AAA battery to produce hydrogen by ... through two electrodes that split liquid water into hydrogen ...
(Date:8/21/2014)... Ga. An international team of scientists including researchers from ... Brassica napus commonly known as canolain the journal Science ... the plant, which is used widely in farming and industry. ... its native Europe, but the winter crop is increasingly cultivated ... its naturally low levels of saturated fat and rich supply ...
Breaking Biology News(10 mins):Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Canola genome sequence reveals evolutionary 'love triangle' 2
... HUNTSVILLE, TX (Feb. 21, 2012)-- An assistant ... Criminal Justice is working to unlock the mysteries ... play on criminal and antisocial behavior. "Biosocial ... behavior," said Dr. Brian Boutwell. "It involves aspects ...
... 2012A team of researchers has found a way to ... to be available, despite the potential attack of Xylella ... poses a significant threat to the California wine industry,s ... Laboratory (LANL), University of California at Davis (UCD), and ...
... prospective study of ethnic differences in the symptoms of ... background have more delayed language, communication and gross motor ... the Kennedy Krieger Institute concluded that subtle developmental delays ... severe symptoms develop. While the prevalence of autism ...
Cached Biology News:Are there biosocial origins for antisocial behavior? 2More grapes, less wrath: Hybrid antimicrobial protein protects grapevines from pathogen 2New study shows minority toddlers with autism are more delayed than affected Caucasian peers 2New study shows minority toddlers with autism are more delayed than affected Caucasian peers 3
... Tissue Array (MSTA) slides were designed to study ... from multiple species. Tissue slices from three ... which can then be treated as a single ... in situ hybridization. This format allows ...
... Clear yellow solution. In ... thimerosal, and other proprietary ... Diluent formulated to stabilize ... antibody conjugates at high ...
... used to predict the melting ... up to 3,200 bases, which ... primers and GC clamps for ... gel electrophoresis (DGGE), constant denaturing ...
... Mini-Sub cell GT cell and PowerPac basic power ... of nucleic acids in agarose gels. The Mini-Sub ... with cables and electrodes, a 7 x 7 ... casting gates, and two 1.5 mm fixed-height combs ...
Biology Products: